mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
A Phase II Study With mFOLFIRINOX as Adjuvent Chemotherapy for Resectable Pancreas Carcinoma
Sponsor: Sun Yat-sen University
Listed as NCT04084496, this PHASE2 trial focuses on Pancreatic Cancer and remains actively recruiting participants. Sponsored by Sun Yat-sen University, it has been updated 7 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Jun 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2024 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Jan 2021 — Mar 2023 [monthly]
Recruiting PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Sep 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .